Even as fireworks exploded into celebratory lights on the Fourth of July, news from Riverside County’s coronavirus test sites put a damper on the holiday: The county surpassed 20,000 detected coronavirus cases on Saturday, a few days before it was expected.By Tuesday, the number had jumped to 21,101 cases, adding 546 cases and 20 new…
Hospital bed and intensive care unit capacity could soon become a concern in the Inland Empire, where coronavirus cases continue to rise in two Southern California counties with the second- and fifth-highest number of cases reported in the state.Across all hospitals in Riverside County, intensive care beds are 99% occupied as of Sunday, said spokeswoman Brooke Federico — a 19% increase…
RIVERSIDE, Calif. (KABC) -- The continued reopening of Riverside County businesses could soon be jeopardized because of the region's failure to meet certain COVID-19 statistical requirements mandated by the state.The county was placed on the state's targeted engagement list on June 17. The region must show improvement within two weeks of that date or risk…
Riverside County has landed on a state watch list for the novel coronavirus following a surge in new cases and hospitalizations from the disease. The county made the California Department of Public Health list after a spike in new cases and a higher percentage of positive tests for COVID-19. As of Friday, June 19, the…
Riverside County health officials Friday announced 250 new coronavirus infections leaving the past week as the highest jumps in cases since the pandemic began. Tuesday there were 384 new cases, 321 on Wednesday and 329 cases on Friday; resulting to more than 1,000 cases this week. Cases countywide now stands at 10,490 with the death…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f